GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkem Laboratories Ltd (NSE:ALKEM) » Definitions » EV-to-EBIT

Alkem Laboratories (NSE:ALKEM) EV-to-EBIT : 30.27 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Alkem Laboratories EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alkem Laboratories's Enterprise Value is ₹595,809 Mil. Alkem Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹19,684 Mil. Therefore, Alkem Laboratories's EV-to-EBIT for today is 30.27.

The historical rank and industry rank for Alkem Laboratories's EV-to-EBIT or its related term are showing as below:

NSE:ALKEM' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.89   Med: 22.53   Max: 33.07
Current: 30.27

During the past 13 years, the highest EV-to-EBIT of Alkem Laboratories was 33.07. The lowest was 13.89. And the median was 22.53.

NSE:ALKEM's EV-to-EBIT is ranked worse than
71.96% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs NSE:ALKEM: 30.27

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alkem Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was ₹622,049 Mil. Alkem Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹19,684 Mil. Alkem Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.16%.


Alkem Laboratories EV-to-EBIT Historical Data

The historical data trend for Alkem Laboratories's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkem Laboratories EV-to-EBIT Chart

Alkem Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.26 22.17 17.63 23.05 28.21

Alkem Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.31 28.21 26.21 22.17 31.60

Competitive Comparison of Alkem Laboratories's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkem Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's EV-to-EBIT falls into.



Alkem Laboratories EV-to-EBIT Calculation

Alkem Laboratories's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=595809.408/19683.5
=30.27

Alkem Laboratories's current Enterprise Value is ₹595,809 Mil.
Alkem Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹19,684 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alkem Laboratories  (NSE:ALKEM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alkem Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=19683.5/622048.869
=3.16 %

Alkem Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was ₹622,049 Mil.
Alkem Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹19,684 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alkem Laboratories EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alkem Laboratories's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkem Laboratories (NSE:ALKEM) Business Description

Traded in Other Exchanges
Address
Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Alkem Laboratories (NSE:ALKEM) Headlines

No Headlines